Article Text

Download PDFPDF

5PSQ-044 Real-life safety and satisfaction of cftr protein modulators in cystic fibrosis
  1. A Ibáñez Zurriaga1,
  2. E Ramírez Herraíz1,
  3. E Pradilla Bascuas2,
  4. M Rodero Nevado2,
  5. RM Girón Moreno3,
  6. V Sanz Cobeña3,
  7. A Garcia Peralo1,
  8. A Álvarez Yuste1,
  9. G Escudero Sanchez1,
  10. A Morell Baladrón1
  1. 1Hospital Universitario de la Princesa, Farmacia, Madrid, Spain
  2. 2Universidad de Alcala, Farmacia, Alcala de Henares Madrid, Spain
  3. 3Hospital Universitario de la Princesa, Neumologia, Madrid, Spain


Background and Importance The new transmembrane conductance regulator (CFTR) modulator drugs (ivacaftor/tezacaftor/elexacaftor) are bringing about a major change in the treatment and quality of life of cystic fibrosis (CF) patients. There is a need to collect information on patient perception of benefit and safety.

Aim and Objectives To assess the satisfaction and adverse effect (AE) profile reported by patients on ivacaftor/tezacaftor/elexacaftor treatment.

Material and Methods Observational, prospective, single-centre study from March to June 2022. CF patients with at least one p.Phe508del mutation in treatment with CFTR modulators. Variables: sociodemographic (age and sex) and biochemical (GOT-ASAT, GPT-ALAT, bilirubin and CPK) collected from patients' medical records. Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) with 14 items in four scales assessing efficacy, side effects, convenience and overall satisfaction from the patient's own perspective, the higher the score, the higher the satisfaction. Adverse Effects Questionnaire (ad hoc), Patient Informed Consent.

Results Out of 58 patients on treatment, 43 answered the questionnaires, 17 (40%) female, median age 30 (26-37). For TSQM the median score for each item was 21 (20-21) over 21; 19 (16-20) over 21; 21 (18-21) over 21 and 17 (16-17) over 17 respectively. Regarding AEs: 39.47% reported increased appetite, 31.58% rash, 23.68% headache, 13.16% runny nose, increased blood pressure, diarrhoea and itchy skin, 10.53% abdominal pain or discomfort, common cold and itchy or stinging eyes and ≤ 2% flatulence, memory loss, yellowing of skin and eyes, muscle pain, fluid retention, insomnia, acne, nausea and vomiting. One patient presented with severe rash requiring discontinuation of treatment. Three months after starting treatment, only three patients had GPT-ASAT >3 LSN and only one patient >5 LSN, one patient had increased CPK >5 LSN and no patient had bilirubin >2 LSN.

Conclusion and Relevance Although a high percentage of patients have experienced AEs, CFTR modulators are widely accepted drugs with a favourable AE profile. The most frequent AEs reported by patients were increased appetite, rash and headache. The AEs described by patients are described in the data sheet. More real-life studies are needed to confirm our study and to provide further evidence.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.